This article proposes i) an economic framework to determine whether and in what circumstances price signalling is likely to have anticompetitive effects, and ii) some thoughts on a desirable standard to be adopted by the Commission in such cases. To read more, click the link below.
What’s 340B? An economist’s view of the recent wave of 340B litigation
But this change has led to complex relationships among pharmaceutical manufacturers, hospitals, pharmacies, and third-party administrators, increasing...